The majority of magnetic resonance contrast agents are restricted to the extracellular domains. For the development of novel, intracellular magnetic resonance contrast agents, we have designed Gd-DOTA derivatives comprising PreS2-TML peptide or ethylguanidinium as carrier moiety. Initial in vitro cell uptake studies with Jurkat cells revealed efficient contrast agent uptake for imaging purposes, in the range of 0.04 fmol/cell (PreS2-TML peptide) to 0.2 fmol/cell (ethylguanidinium) following 2 h incubations at 100 µM.
|Faculties / Institutes:||Service facilities > German Cancer Research Center (DKFZ)|
|Subjects:||610 Medical sciences Medicine|
|Controlled Keywords:||NMR-Bildgebung, Kontrastmittel|
|Uncontrolled Keywords:||MRI , contrats agent, guanidinium , PreS2TML|